Snowden Capital Advisors’s TherapeuticsMD TXMD Stock Holding History

Snowden Capital Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	1988
2021 Q4	$0	Buy	+4	New	+$120	﹤0.01%	2155

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Snowden Capital Advisors's TXMD Position: Q1 2022 in Review

Snowden Capital Advisors sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 4 shares.

Snowden Capital Advisors first reported a position in TXMD in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

Snowden Capital Advisors reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 4 TherapeuticsMD shares in Q1 2022.
Snowden Capital Advisors first reported a position in TherapeuticsMD in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's TherapeuticsMD position peaked at $0 in Q4 2021.
124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.